Psoriasis – Landscape & Forecast – Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and the interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is increasingly being challenged by highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been strong, raising an alarm for other approved biologics. The recent approvals of deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor, and the nonsteroidal topical agents roflumilast and tapinarof have further increased the number of psoriasis treatments, making the market even more competitive. The anticipated U.S. approval of bimekizumab, an IL-17A/F inhibitor, will further intensify competition among targeted therapies.

Questions answered:

  • How do interviewed KOLs view the efficacy and safety of the established IL-17 inhibitors (Cosentyx, Taltz, Siliq / Lumicef) and the novel IL-17 A/F dual inhibitor bimekizumab (UCB’s Bimzelx), and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of newer IL-23 inhibitors (Ilumya and Skyrizi) on other approved biologics? How are/will these newer agents fare in the competitive psoriasis market?
  • How will the launch of biosimilar adalimumab in the United States impact psoriasis market?
  • How will the oral TYK2 inhibitor deucravacitinib (BMS’s Sotyktu) affect apremilast’s (Amgen’s Otezla) patient share, and how do the two agents compare on efficacy and safety attributes?
  • What will be the future of the novel topical nonsteroidal therapies roflumilast (Arcutis’s Zoryve), and tapinarof (Dermavant’s Vtama)?

Content highlights:

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 36 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.

Emerging therapies: Phase 3/PR: 3 drugs; Phase 2: 10 drugs; coverage of select early-phase products.

Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2032, segmented by brands/generics and epidemiological subpopulations.

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement:

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports